Cargando…
Report from the EMA workshop on qualification and reporting of physiologically based pharmacokinetic (PBPK) modeling and simulation
On Nov 21, 2016, the European Medicines Agency (EMA) hosted a workshop to discuss its draft guideline on qualification and reporting of physiologically based pharmacokinetic (PBPK) analysis.(1) Published on July 21, 2016, the draft PBPK guideline is currently under the period of public comments.
Autor principal: | Zhao, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321806/ https://www.ncbi.nlm.nih.gov/pubmed/28035755 http://dx.doi.org/10.1002/psp4.12166 |
Ejemplares similares
-
Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015) -
The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop
por: Manolis, E, et al.
Publicado: (2013) -
Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development
por: Shaik, Abdul Naveed, et al.
Publicado: (2019) -
Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry
por: Rowland, M
Publicado: (2013) -
An Integrated Approach for Assessing the Impact of Renal Impairment on Pharmacokinetics of Drugs in Development: Pivotal Role of PBPK Modelling
por: Rowland Yeo, Karen, et al.
Publicado: (2021)